Cargando…
Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients: A systematic review and meta-analysis of randomized controlled trials
Alemtuzumab (ALEM) is widely used as an induction therapy for organ transplantation, and numerous randomized controlled trials (RCTs) have been published to evaluate its efficacy and safety in kidney transplantation as compared with antithymocyte globulin (ATG). The purpose of this study was to comp...
Autores principales: | Zheng, Jianming, Song, Wenli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515737/ https://www.ncbi.nlm.nih.gov/pubmed/28700465 http://dx.doi.org/10.1097/MD.0000000000007151 |
Ejemplares similares
-
Tailored Rabbit Antithymocyte Globulin Induction Dosing for Kidney Transplantation
por: Singh, Namita, et al.
Publicado: (2018) -
Timing of rabbit antithymocyte globulin induction therapy in kidney transplantation: an observational cohort study
por: Harrison, Jennifer J, et al.
Publicado: (2014) -
Retrospective Evaluation of Rabbit Antithymocyte Globulin Induction in Heart Transplant Patients
por: Lee, Grace Pui-Yun, et al.
Publicado: (2022) -
Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched analysis within the Korean multicentric registry
por: Lee, Jun Young, et al.
Publicado: (2022) -
Induction with Rabbit Antithymocyte Globulin following Orthotopic Liver Transplantation for Hepatitis C
por: Saidi, R. F., et al.
Publicado: (2011)